Sanofi’s COBRA Research to Tackle the Challenge of A Universal Influenza Vaccine for Winter

12/11/2015 - 3 minutes

Sanofi Pasteur is the infectious disease division of the French Giant Sanofi, responsible for producing 1 Billion vaccine doses each year. Now they are looking to ‘evolve’ the vaccine R&D field, adapting their approach to find a broader spectrum defense against seasonal Influenza strains. However, the UK NIHR and PepTCell are also after the same thing.

Sanofi presented its new Research and development focus at the 16th World Vaccine Congress in Madrid (Spain). Seeing as Europe continues to strive in its leading position in the vaccine field (Sanofi being one of its 3 major manufacturing giants), it has long been expected for Sanofi to also pursue a ‘Universal Vaccine‘ for seasonal flu, which annually kills 250,000 to 500,000 people. According to Sanofi Pasteur’s CEO Olivier Charmeil, Sanofi already provides over 220 million seasonal influenza vaccine doses each year to combat these figures from the WHO.

As Charmeil explained, this simply isn’t enough though, due to the rapidly changing nature of such viruses.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!